- Home
- ORIC vs EOS Comparison
ORIC vs EOS Comparison
Compare ORIC & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORIC | EOS |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ORIC | EOS |
|---|---|---|
| Price | $9.11 | $20.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $21.93 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 165.1K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $19.44 |
| 52 Week High | $14.68 | $24.03 |
Technical Indicators
Market Signals| Indicator | ORIC | EOS |
|---|---|---|
| Relative Strength Index (RSI) | 29.39 | 36.00 |
| Support Level | $7.40 | $19.44 |
| Resistance Level | $9.13 | $21.69 |
| Average True Range (ATR) | 1.05 | 0.24 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 1.79 | 14.40 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.